OCUL today
$6.28-$0.38 (-5.71%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns up above $7.75
Key levels
Resistance$7.54
Resistance$6.79
Support$6.00
Support$5.11
Latest news & SEC filings
AnalystRBC Capital keeps Buy rating and $30 target on Ocular Therapeutix
AnalystHC Wainwright keeps Buy rating on Ocular Therapeutix, lifts target to $28
EarningsOcular Therapeutix holds Q3 2026 earnings call
All OCUL news →About Ocular Therapeutix
Ocular Therapeutix is a biopharmaceutical company focused on treatments for retinal and other eye diseases. Its commercial product, DEXTENZA, is an FDA-approved corticosteroid insert for ocular inflammation and pain after eye surgery and for allergic conjunctivitis itching. The company is developing AXPAXLI, an axitinib-based hydrogel implant for wet age-related macular degeneration and diabetic retinal disease, and OTX-TIC for glaucoma or ocular hypertension. It operates in the United States and has a collaboration covering certain Asian markets.
Based on the company's 10-K filed Feb 5, 2026.
Nasdaq · Healthcare
OCULAR THERAPEUTIX, INC (OCUL)
What Is the Price Target for OCUL?
SEPT Low Target
$14.00
SEPT Mid Target
$20.50
SEPT High Target
$30.00
Analyst Consensus
$20.50
Is OCUL a Buy or Sell Right Now?
Thesis
- •Revenue growing -18.5% YoY with SLOWING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for OCUL.
Start Free Trial →Is OCUL Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$16.80
16
Moat Score
NONE
4/9
Piotroski Score
2.7
Altman Z-Score
What Is Smart Money Doing with OCUL?
Insider Signal
SELLING
0 buys / 11 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Sherif Riad | director | Buy | 28,000 | - | Nov 6, 2026 |
| Kaiser Peter | officer | Sale | 9,990 | $70K | Oct 2, 2026 |
| Heier Jeffrey S. | officer | Sale | 10,869 | $77K | Oct 2, 2026 |
| Notman Donald | officer | Sale | 1,099 | $11K | Aug 31, 2026 |
| Kaiser Peter | officer | Sale | 3,035 | $33K | Aug 24, 2026 |
| Warden Charles M | director | Buy | 14,000 | - | Jun 10, 2026 |
| Graves Adrienne L | director | Buy | 14,000 | - | Jun 10, 2026 |
| Robins Jason Shand | officer | Buy | 15,441 | - | Jun 10, 2026 |
| Hong Seung Suh | director | Buy | 14,000 | - | Jun 10, 2026 |
| LINDSTROM RICHARD L MD | director | Buy | 14,000 | - | Jun 10, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →OCUL Growth Story
Revenue YoY
-18.5%
3yr Revenue CAGR
0.3%
EPS Growth YoY
-16.39%
FCF Growth YoY
-59.5%
Revenue Trend
SLOWING
Dark Pool Trades for OCUL
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for OCUL, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:43 | $6.28 | 10,787 | $$68K | SELL |
| 21:00:43 | $6.28 | 8,146 | $$51K | SELL |
| 21:00:02 | $6.28 | 5,100 | $$32K | SELL |
| 21:00:02 | $6.28 | 1,420 | $$9K | SELL |
| 21:00:00 | $6.28 | 2,400 | $$15K | SELL |
5 dark pool trades shown · $$175K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for OCUL
PREVIEWSEPT Investing provides real-time options flow tracking for OCUL, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $7 | Dec 18 | 36 | $$35 | 1 | SWEEP |
| CALL | $7 | Dec 18 | 36 | $$215 | 43 | SWEEP |
| PUT | $5 | Mar 19 | 127 | $$900 | 20 | SWEEP |
3 options trades shown · 67% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for OCULAR THERAPEUTIX, INC (OCUL) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (5 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →OCUL — frequently asked questions
What is OCUL stock price today?
OCULAR THERAPEUTIX, INC (OCUL) is at $6.28, down 5.71% (-$0.38) at the Nov 12, 2026 close.
Why is OCUL stock moving today?
Latest OCUL news — Nov 11, 2026: RBC Capital keeps Buy rating and $30 target on Ocular Therapeutix · Nov 10, 2026: HC Wainwright keeps Buy rating on Ocular Therapeutix, lifts target to $28
Why did OCUL stock move on Nov 9, 2026?
Ocular Therapeutix shares closed at $6.85, up 9.60% on volume of over 3.3 million shares, despite reporting a wider-than-expected quarterly loss of $0.42 per share versus the $0.36 loss analysts expected and revenue of $12.874 million that fell short of the $14.339 million estimate. The company also held its Q3 2026 earnings call and filed two Form 8-K reports covering major company events.
What is the OCUL price target?
The average analyst price target for OCUL is $20.50, ranging from $14 to $30, based on 4 analysts.
What do analysts rate OCUL?
Analyst ratings for OCUL: 12 Buy, 0 Hold, 0 Sell — consensus Strong Buy.
Did OCUL beat earnings?
OCUL last reported on Nov 9, 2026: EPS -$0.42 vs -$0.36 expected — a miss of 16.7%.
Does OCUL pay a dividend?
OCUL does not currently pay a dividend.
What are OCUL support and resistance levels?
Support: $6.00, $5.11, $4.06. Resistance: $6.79, $7.54, $8.15.
What are insiders doing with OCUL?
Insider activity: SELLING, 0 buys and 11 sells in the last 90 days.
What is the latest news on OCUL?
Nov 11, 2026: RBC Capital keeps Buy rating and $30 target on Ocular Therapeutix · Nov 10, 2026: HC Wainwright keeps Buy rating on Ocular Therapeutix, lifts target to $28 · Nov 9, 2026: Ocular Therapeutix holds Q3 2026 earnings call